Biotechnology

Sep 16, 2024, 07:00 ET Nanoscope Therapeutics Announces Presentations at Euretina Innovation Spotlight and Ophthalmology Futures Forum in Barcelona

Nanoscope Therapeutics Inc., a clinical-stage biotechnology company developing gene therapies for inherited retinal diseases, and geographic atrophy...

Sep 16, 2024, 07:00 ET Scinai to Host Online Expert Panel on Plaque Psoriasis Treatment and Intralesional Injections of anti-IL-17A/F VHH Antibodies

Scinai Immunotherapeutics Ltd. (Nasdaq: SCNI) ("Scinai" or the "Company"), a biopharmaceutical company specializing in inflammation and immunology...

Sep 16, 2024, 06:00 ET Antennova Releases Latest Data of CD73 Inhibitor ATN-037, including a DCR of 89.5%, in a Mini Oral at ESMO Congress 2024

Antennova, a clinical-stage biotech company focused on oncology today announced that it presented the latest data of CD73 small molecule inhibitor...

Sep 16, 2024, 02:00 ET Zulassung des ersten Medizinproduktes zur Behandlung von Fibromyalgie in Europa

Sep 16, 2024, 02:00 ET Le premier dispositif médical dédié au traitement de la fibromyalgie autorisé en Europe

Sep 16, 2024, 02:00 ET Remedee Labs' Solution becomes the first CE marked medical device (class IIa) approved for the treatment of fibromyalgia in Europe

Remedee Labs, a French start-up that specializes in non-pharmacological treatments for chronic pain, is announcing today that it has obtained medical ...

Sep 16, 2024, 00:00 ET Trailhead Biosystems Announces Joshua Snow as Chief Commercial Officer

Trailhead Biosystems, Inc. (trailbio.com), a biotechnology company creating iPSC-derived human cells at scale for drug discovery and cell therapy,...

Sep 15, 2024, 21:24 ET 耶鲁大学医学院因在罕见病遗传学方面的卓越成就而受到美国国立卫生研究院的表彰

Sep 15, 2024, 15:01 ET TORL BioTherapeutics Presents Updated Phase 1 Results of Novel Claudin 6 Targeted Antibody-Drug Conjugate TORL-1-23 at the 2024 European Society of Medical Oncology Congress

TORL BioTherapeutics, LLC ("TORL Bio" or "the Company"), a clinical stage biotechnology company discovering and developing new antibody-based...

Sep 15, 2024, 05:53 ET ESMO 2024 - ImmVira Unveils Clinical Results of Intravesical MVR-T3011 for High-Risk BCG-Failure NMIBC Patients

ImmVira announced the latest clinical results for its lead oncolytic virus product, MVR-T3011, via intravesical administration in patients with...

Sep 14, 2024, 13:28 ET La Escuela de Medicina de Yale recibe reconocimiento por parte de los NIH por su excelencia en genética de enfermedades raras

Sep 14, 2024, 09:00 ET SOPHiA GENETICS Presents Ground-Breaking Multimodal Research on AI-Driven Patient Stratification at ESMO 2024

SOPHiA GENETICS (Nasdaq: SOPH), a cloud-native healthcare technology company and a leader in data-driven medicine, will unveil new research at the...

Sep 14, 2024, 09:00 ET Adela Announces Clinical Validation Results for Head & Neck Cancer MRD Test Simultaneously Published in Annals of Oncology and Presented at ESMO 2024

Adela, Inc., an innovator in blood testing for molecular residual disease (MRD) monitoring and early cancer detection through a proprietary...

Sep 14, 2024, 07:00 ET Gan & Lee Pharmaceuticals Presented Two Positive Clinical Results of Once-weekly Insulin GZR4 at the 60th Annual Meeting of the European Association for the Study of Diabetes (EASD 2024)

Gan & Lee Pharmaceuticals (Gan & Lee, Shanghai Stock Exchange: 603087) announced the clinical results from two Phase I trials of the Company's...

Sep 14, 2024, 05:00 ET Nuvalent Highlights Presentation of Clinical Data at ESMO 2024 for Parallel Lead Programs for ROS1 and ALK-positive NSCLC and Accelerated Development Timelines

Nuvalent, Inc. (Nasdaq: NUVL), a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for clinically proven...

Sep 14, 2024, 04:06 ET Harbour BioMed Announces the Latest Clinical Data on the First-in-Class Fully Human Anti-B7H7/HHLA2 Monoclonal Antibody HBM1020 at the ESMO Congress 2024

Harbour BioMed (the "Company"; HKEX: 02142), a global biopharmaceutical company committed to the discovery, development, and commercialization of...

Sep 13, 2024, 20:14 ET Live from ESMO 2024 | Ascentage Pharma Releases Latest Data Showing Sustained Clinical Efficacy of Olverembatinib in SDH-Deficient GIST during a Mini Oral Presentation

Ascentage Pharma (6855.HK), a global biopharmaceutical company engaged in discovering, developing and commercializing therapies to address global...